These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
504 related articles for article (PubMed ID: 26312963)
1. Sleep-disordered breathing in patients with opioid use disorders in long-term maintenance on buprenorphine-naloxone: A case series. DeVido J; Connery H; Hill KP J Opioid Manag; 2015; 11(4):363-6. PubMed ID: 26312963 [TBL] [Abstract][Full Text] [Related]
2. Case of buprenorphine-associated central sleep apnea resolving with dose reduction. Tchikrizov V; Richert AC; Bhardwaj SB J Opioid Manag; 2022; 18(4):391-394. PubMed ID: 36052936 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial. Webster L; Hjelmström P; Sumner M; Gunderson EW J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785 [TBL] [Abstract][Full Text] [Related]
5. The effects of buprenorphine/naloxone maintenance treatment on sexual dysfunction, sleep and weight in opioid use disorder patients. Baykara S; Alban K Psychiatry Res; 2019 Feb; 272():450-453. PubMed ID: 30611963 [TBL] [Abstract][Full Text] [Related]
6. Inpatient initiation of buprenorphine maintenance vs. detoxification: can retention of opioid-dependent patients in outpatient counseling be improved? Caldiero RM; Parran TV; Adelman CL; Piche B Am J Addict; 2006; 15(1):1-7. PubMed ID: 16449087 [TBL] [Abstract][Full Text] [Related]
7. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data. Debelak K; Morrone WR; O'Grady KE; Jones HE Am J Addict; 2013; 22(3):252-4. PubMed ID: 23617867 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone. Sekar V; Tomaka F; Lefebvre E; De Pauw M; Vangeneugden T; van den Brink W; Hoetelmans R J Clin Pharmacol; 2011 Feb; 51(2):271-8. PubMed ID: 20421512 [No Abstract] [Full Text] [Related]
9. Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence. Orman JS; Keating GM Drugs; 2009; 69(5):577-607. PubMed ID: 19368419 [TBL] [Abstract][Full Text] [Related]
10. Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone? Srivastava A; Kahan M; Nader M Can Fam Physician; 2017 Mar; 63(3):200-205. PubMed ID: 28292795 [TBL] [Abstract][Full Text] [Related]
11. The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia. Horyniak D; Dietze P; Larance B; Winstock A; Degenhardt L Int J Drug Policy; 2011 Mar; 22(2):167-71. PubMed ID: 21112758 [TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study. Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242 [TBL] [Abstract][Full Text] [Related]
13. Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients. DiPaula BA; Menachery E J Am Pharm Assoc (2003); 2015; 55(2):187-92. PubMed ID: 25749264 [TBL] [Abstract][Full Text] [Related]
14. The effect of buprenorphine vs methadone on sleep breathing disorders. Adimi Naghan P; Setareh J; Malekmohammad M Adv Respir Med; 2021; 89(4):439-443. PubMed ID: 33871044 [TBL] [Abstract][Full Text] [Related]
15. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence. Mammen K; Bell J Expert Opin Pharmacother; 2009 Oct; 10(15):2537-44. PubMed ID: 19708849 [TBL] [Abstract][Full Text] [Related]
16. Elective Naloxone-Induced Opioid Withdrawal for Rapid Initiation of Medication-Assisted Treatment of Opioid Use Disorder. Phillips RH; Salzman M; Haroz R; Rafeq R; Mazzarelli AJ; Pelletier-Bui A Ann Emerg Med; 2019 Sep; 74(3):430-432. PubMed ID: 30773411 [TBL] [Abstract][Full Text] [Related]
17. Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder. Bishop B; Gilmour J; Deering D Int J Ment Health Nurs; 2019 Feb; 28(1):226-236. PubMed ID: 30019812 [TBL] [Abstract][Full Text] [Related]
18. Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults. Cottrill CB; Matson SC Adolesc Med State Art Rev; 2014 Aug; 25(2):251-65. PubMed ID: 27132312 [No Abstract] [Full Text] [Related]
19. Medically assisted recovery from opiate dependence within the context of the UK drug strategy: methadone and Suboxone (buprenorphine-naloxone) patients compared. McKeganey N; Russell C; Cockayne L J Subst Abuse Treat; 2013 Jan; 44(1):97-102. PubMed ID: 22703715 [TBL] [Abstract][Full Text] [Related]
20. Buprenorphine-naloxone treatment in opioid dependence and risk of liver enzyme elevation: results from a 12-month observational study. Soyka M; Backmund M; Schmidt P; Apelt S Am J Addict; 2014; 23(6):563-9. PubMed ID: 25251050 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]